Human studies of glucagon receptor antagonism show a striking result: hepatic amino-acid clearance drops hyperaminoacidaemia develops skeletal muscle becomes the fallback source of amino acids This pattern mirrors the very changes we see under GLP-1RA therapy
Obesity and insulin resistance sustain elevated circulating concentrations of pro-inflammatory cytokines including Tumour Necrosis Factor-alpha (TNF-), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) molecules that promote DNA damage, tumour angiogenesis, and immune evasion
The answer depends entirely on the concentration of your specific formulation
Improved blood flow may deliver more oxygen and nutrients to working muscles, potentially enhancing performance, although clinical evidence for performance enhancement remains mixed
any such changes are more likely related to weight loss, hormonal shifts, or psychological factors
In one study, people with overweight or obesity who took semaglutide lost around 6% of their body weight after three months and nearly 11% after six months